Allopurinol Reduces B-type Natriuretic Peptide Concentrations and Haemoglobin but Does Not Alter Exercise Capacity in Chronic Heart Failure

Overview

Journal Heart

Date 2005 May 17

PMID 15894768

Citations 42

Authors

A D Gavin

A D Struthers

Affiliations

Soon will be listed here.

Abstract

Objective: To study whether the effect of allopurinol on improvement of endothelial dysfunction in chronic heart failure (CHF) translates into improved exercise capacity and to examine whether allopurinol also improves B-type natriuretic peptide (BNP), the other important prognostic marker of CHF.

Design: Randomised, double blind, placebo controlled crossover trial.

Setting: Teaching hospital.

Patients: 50 patients with CHF (New York Heart Association functional classes II and III) were recruited.

Interventions: 50 patients with CHF were randomly assigned to three months' treatment with allopurinol (300 mg/day) or placebo. At two and three months into treatment, they underwent a modified Bruce exercise protocol and a six minute walk test. Blood was taken for BNP and haemoglobin analysis.

Results: Neither exercise test was altered by allopurinol. However, plasma BNP concentrations fell significantly (p = 0.035) with allopurinol (11.9 pmol/l) versus placebo (14.4 pmol/l). Haemoglobin concentrations also fell highly significantly with allopurinol (p = 0.001).

Conclusions: An important negative finding is that despite high hopes for it, allopurinol had no effect on exercise capacity in CHF. On the other hand, allopurinol did reduce BNP, which is the best available surrogate marker for prognosis in CHF.

Citing Articles

Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study.

Yokota T, Kinugawa S, Fukushima A, Okumura T, Murohara T, Tsutsui H Heart Vessels. 2024; 40(2):111-122.

PMID: 39158751 DOI: 10.1007/s00380-024-02448-9.

Update in uric acid, hypertension, and cardiovascular diseases.

Kuwabara M, Kodama T, Ae R, Kanbay M, Andres-Hernando A, Borghi C Hypertens Res. 2023; 46(7):1714-1726.

PMID: 37072573 DOI: 10.1038/s41440-023-01273-3.

Notopterol Ameliorates Hyperuricemia-Induced Cardiac Dysfunction in Mice.

Wang Q, Peng D, Huang B, Men L, Jiang T, Huo S Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986461 PMC: 10052463. DOI: 10.3390/ph16030361.

Sodium glucose co-transport 2 inhibitors for gout treatment.

Somagutta M, Luvsannyam E, Jain M, Cuddapah G, Pelluru S, Mustafa N Discoveries (Craiova). 2022; 10(3):e152.

PMID: 36540089 PMC: 9759282. DOI: 10.15190/d.2022.11.

Coenzyme Q Reduces Infarct Size in Animal Models of Myocardial Ischemia-Reperfusion Injury: A Meta-Analysis and Summary of Underlying Mechanisms.

Awad K, Sayed A, Banach M Front Cardiovasc Med. 2022; 9:857364.

PMID: 35498032 PMC: 9053645. DOI: 10.3389/fcvm.2022.857364.

References

ODriscoll J, Green D, Rankin J, Taylor R . Nitric oxide-dependent endothelial function is unaffected by allopurinol in hypercholesterolaemic subjects. Clin Exp Pharmacol Physiol. 1999; 26(10):779-83. DOI: 10.1046/j.1440-1681.1999.03125.x. View

Cowie M, Struthers A, Wood D, Coats A, Thompson S, Poole-Wilson P . Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997; 350(9088):1349-53. DOI: 10.1016/S0140-6736(97)06031-5. View

Suwaidi J, Hamasaki S, Higano S, Nishimura R, Holmes Jr D, Lerman A . Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101(9):948-54. DOI: 10.1161/01.cir.101.9.948. View

Butler R, Morris A, Belch J, Hill A, Struthers A . Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000; 35(3):746-51. DOI: 10.1161/01.hyp.35.3.746. View

Danesh J, Collins R, Peto R, Lowe G . Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J. 2000; 21(7):515-20. DOI: 10.1053/euhj.1999.1699. View

Schachinger V, Britten M, Zeiher A . Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000; 101(16):1899-906. DOI: 10.1161/01.cir.101.16.1899. View

Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S . Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res. 2000; 87(5):392-8. DOI: 10.1161/01.res.87.5.392. View

Mak S, Newton G . Vitamin C augments the inotropic response to dobutamine in humans with normal left ventricular function. Circulation. 2001; 103(6):826-30. DOI: 10.1161/01.cir.103.6.826. View

McDonagh T, Cunningham A, Morrison C, McMurray J, Ford I, Morton J . Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart. 2001; 86(1):21-6. PMC: 1729832. DOI: 10.1136/heart.86.1.21. View

10.

Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A . Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001; 104(2):191-6. DOI: 10.1161/01.cir.104.2.191. View

11.

Patel R, Nagueh S, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen H . Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 2001; 104(3):317-24. PMC: 2768618. DOI: 10.1161/hc2801.094031. View

12.

Di Napoli P, Antonio Taccardi A, Grilli A, Spina R, Felaco M, Barsotti A . Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res. 2001; 51(2):283-93. DOI: 10.1016/s0008-6363(01)00306-6. View

13.

de Lemos J, Morrow D, Bentley J, Omland T, Sabatine M, McCabe C . The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001; 345(14):1014-21. DOI: 10.1056/NEJMoa011053. View

14.

Drexler H . Endothelium as a therapeutic target in heart failure. Circulation. 1998; 98(24):2652-5. DOI: 10.1161/01.cir.98.24.2652. View

15.

Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R . Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation. 1998; 98(24):2709-15. DOI: 10.1161/01.cir.98.24.2709. View

16.

Cappola T, Kass D, Nelson G, Berger R, Rosas G, Kobeissi Z . Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001; 104(20):2407-11. DOI: 10.1161/hc4501.098928. View

17.

Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y . Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001; 108(10):1429-37. PMC: 209420. DOI: 10.1172/JCI13350. View

18.

Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T . Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001; 104(22):2673-8. DOI: 10.1161/hc4601.099485. View

19.

Struthers A, Donnan P, Lindsay P, McNaughton D, Broomhall J, MacDonald T . Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart. 2002; 87(3):229-34. PMC: 1767024. DOI: 10.1136/heart.87.3.229. View

20.

Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T . Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002; 105(7):868-73. DOI: 10.1161/hc0702.104164. View